OSCR · Company research
Oscar Health, Inc. (OSCR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
65records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| CNC, OSCR Stocks Rally After Baird Calls Risk Adjustment Results Favorable - Stocktwits | CNC, OSCR Stocks Rally After Baird Calls Risk Adjustment Results Favorable Stocktwits | View source ↗ | Stocktwits | Oct 18, 2026 | neutral | 0 | 0.6 |
| Oscar Health, Inc. $OSCR Stock: Assenagon Asset Management S.A. Increases Position - MarketBeat | Oscar Health, Inc. $OSCR Stock: Assenagon Asset Management S.A. Increases Position MarketBeat | View source ↗ | MarketBeat | Oct 17, 2026 | neutral | 0 | 0.6 |
| Oscar Health Inc (OSCR) Shares Fall 4.7% -- GF Value Says Still Overvalued - GuruFocus | Oscar Health Inc (OSCR) Shares Fall 4.7% -- GF Value Says Still Overvalued GuruFocus | View source ↗ | GuruFocus | Oct 16, 2026 | neutral | 0 | 0.6 |
| Oscar Health vs. Molina: Which Healthcare Stock Is a Better Buy? | Oscar Health (OSCR) is positioned as the stronger investment compared to Molina Healthcare (MOH), driven by robust 46% membership growth, 70% revenue increase, a 20% revenue CAGR target through 2027, and a lower valuation multiple. Molina faces headwinds from rising medical costs, enrollment challenges, and portfolio restructuring, with a projected 2027 exit from its MAPD business and $1 billion marketplace premium reduction. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 1 |
| Are Finance Stocks Lagging ASX Limited - Unsponsored ADR (ASXFY) This Year? | ASX Limited - Unsponsored ADR (ASXFY) is significantly outperforming the Finance sector year-to-date, returning 26.3% compared to the sector average of 3.3%. The stock holds a Zacks Rank #1 (Strong Buy) with analyst sentiment improving, as consensus earnings estimates have risen 9.9% in the past quarter. Oscar Health, Inc. (OSCR) is another standout performer in the Finance sector with 132.9% year-to-date returns and a Zacks Rank #1 rating. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Are Finance Stocks Lagging ASX Limited - Unsponsored ADR (ASXFY) This Year? | ASX Limited - Unsponsored ADR (ASXFY) is significantly outperforming the Finance sector year-to-date, returning 26.3% compared to the sector average of 3.3%. The stock holds a Zacks Rank #1 (Strong Buy) with analyst sentiment improving, as consensus earnings estimates have risen 9.9% in the past quarter. Oscar Health, Inc. (OSCR) is another standout performer in the Finance sector with 132.9% year-to-date returns and a Zacks Rank #1 rating. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Zacks Investment Ideas feature highlights: CoreWeave, Cinemark, Oscar Health and Heico | Despite recent market volatility driven by AI concerns, rising rates, and geopolitical tensions, three stocks with strong Zacks Rank #1 ratings stand out: Cinemark benefits from theater attendance recovery and pricing power, Oscar Health is transitioning to profitability with surging membership growth, and Heico demonstrates consistent aerospace and defense sector strength. All three show improving earnings estimates and constructive technical setups independent of AI boom dependency. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.6 | 1 |
| Zacks Investment Ideas feature highlights: CoreWeave, Cinemark, Oscar Health and Heico | Despite recent market volatility driven by AI concerns, rising rates, and geopolitical tensions, three stocks with strong Zacks Rank #1 ratings stand out: Cinemark benefits from theater attendance recovery and pricing power, Oscar Health is transitioning to profitability with surging membership growth, and Heico demonstrates consistent aerospace and defense sector strength. All three show improving earnings estimates and constructive technical setups independent of AI boom dependency. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.6 | 1 |
| Oscar Health, Inc. (OSCR) Stock Sinks As Market Gains: Here's Why | Oscar Health (OSCR) closed at $33.47, down 2.48% on the trading day. The company is rated Zacks Rank #1 (Strong Buy) with an upcoming earnings release on November 5, 2026. Analysts expect EPS of -$0.11 and revenue of $4.72 billion for the quarter, with full-year forecasts of $1.83 EPS and $18.81 billion revenue. The stock trades at a Forward P/E of 18.72, above the industry average of 10.07, with a PEG ratio of 0.38. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Oscar Health, Inc. (OSCR) Stock Sinks As Market Gains: Here's Why | Oscar Health (OSCR) closed at $33.47, down 2.48% on the trading day. The company is rated Zacks Rank #1 (Strong Buy) with an upcoming earnings release on November 5, 2026. Analysts expect EPS of -$0.11 and revenue of $4.72 billion for the quarter, with full-year forecasts of $1.83 EPS and $18.81 billion revenue. The stock trades at a Forward P/E of 18.72, above the industry average of 10.07, with a PEG ratio of 0.38. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Oscar Health, Inc. (OSCR) Stock Sinks As Market Gains: Here's Why - Yahoo Finance | Oscar Health, Inc. (OSCR) Stock Sinks As Market Gains: Here's Why Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| 3 Top Ranked Stocks Gaining Despite Market Turmoil | Amid market volatility triggered by rising interest rates, inflation concerns, and AI sector weakness, three stocks with strong earnings momentum stand out: Cinemark benefits from theater attendance recovery and pricing power, Oscar Health is transitioning to profitability with surging membership growth, and HEICO demonstrates consistent aerospace and defense sector strength. All three carry Zacks Rank #1 ratings and offer exposure outside the dominant AI investment theme. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.6 | 1 |
| 3 Top Ranked Stocks Gaining Despite Market Turmoil | Amid market volatility triggered by rising interest rates, inflation concerns, and AI sector weakness, three stocks with strong earnings momentum stand out: Cinemark benefits from theater attendance recovery and pricing power, Oscar Health is transitioning to profitability with surging membership growth, and HEICO demonstrates consistent aerospace and defense sector strength. All three carry Zacks Rank #1 ratings and offer exposure outside the dominant AI investment theme. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.6 | 1 |
| Best Growth Stocks to Buy for October 15th | Stock markets declined following a higher-than-expected CPI inflation report. The article highlights three stocks with Zacks Rank #1 buy ratings: Petco Health and Wellness (WOOF), Five Below (FIVE), and Oscar Health (OSCR), all showing strong earnings estimate increases and favorable PEG ratios compared to their respective industry averages. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Best Growth Stocks to Buy for October 15th | Stock markets declined following a higher-than-expected CPI inflation report. The article highlights three stocks with Zacks Rank #1 buy ratings: Petco Health and Wellness (WOOF), Five Below (FIVE), and Oscar Health (OSCR), all showing strong earnings estimate increases and favorable PEG ratios compared to their respective industry averages. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Oscar Health, Inc. (OSCR) Rises As Market Takes a Dip: Key Facts | Oscar Health (OSCR) closed at $34.32, up 1.57%, outperforming the S&P 500's decline. The company has gained 4.16% over the past month. With an upcoming earnings report expected November 5, 2026, analysts project EPS of -$0.11 and revenue of $4.72 billion. For the full fiscal year, projections show EPS of $1.83 and revenue of $18.81 billion. OSCR holds a Zacks Rank #1 (Strong Buy) rating with consensus EPS projections up 18.79% in the past 30 days, though it trades at a premium valuation with a Forward P/E of 18.43 versus the industry average of 10.09. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Oscar Health, Inc. (OSCR) is a Top-Ranked Momentum Stock: Should You Buy? | Oscar Health (OSCR), a healthcare technology company offering ACA health plans, has been identified as a strong momentum stock with a Zacks Rank #1 (Strong Buy) rating and a VGM Score of A. The company has seen three upward earnings estimate revisions in the last 60 days, with consensus estimates increasing to $1.83 per share for fiscal 2026, and shares are up 4.2% over the past four weeks. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Oscar Health, Inc. (OSCR) is a Top-Ranked Momentum Stock: Should You Buy? | Oscar Health (OSCR), a healthcare technology company offering ACA health plans, has been identified as a strong momentum stock with a Zacks Rank #1 (Strong Buy) rating and a VGM Score of A. The company has seen three upward earnings estimate revisions in the last 60 days, with consensus estimates increasing to $1.83 per share for fiscal 2026, and shares are up 4.2% over the past four weeks. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| This Top Finance Stock is a #1 (Strong Buy): Why It Should Be on Your Radar | Oscar Health, Inc. (OSCR) has been added to the Zacks Rank #1 (Strong Buy) list on September 23, 2026. The healthcare technology company has received upward earnings estimate revisions from three analysts, with consensus estimates increasing to $1.83 per share. Analysts expect 208.3% earnings growth and 60.8% revenue growth for the current fiscal year, with the stock up 4.2% over the past four weeks. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| This Top Finance Stock is a #1 (Strong Buy): Why It Should Be on Your Radar | Oscar Health, Inc. (OSCR) has been added to the Zacks Rank #1 (Strong Buy) list on September 23, 2026. The healthcare technology company has received upward earnings estimate revisions from three analysts, with consensus estimates increasing to $1.83 per share. Analysts expect 208.3% earnings growth and 60.8% revenue growth for the current fiscal year, with the stock up 4.2% over the past four weeks. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Why Fast-paced Mover Oscar Health (OSCR) Is a Great Choice for Value Investors | Oscar Health (OSCR) is highlighted as an attractive investment opportunity combining momentum with value. The stock has gained 4.2% over four weeks and 9.8% over 12 weeks, with a beta of 2.47 indicating high volatility. Despite strong momentum metrics and a Zacks Rank #1 (Strong Buy) rating driven by upward earnings estimate revisions, OSCR trades at a reasonable valuation with a Price-to-Sales ratio of 0.68, suggesting significant upside potential. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Why Fast-paced Mover Oscar Health (OSCR) Is a Great Choice for Value Investors | Oscar Health (OSCR) is highlighted as an attractive investment opportunity combining momentum with value. The stock has gained 4.2% over four weeks and 9.8% over 12 weeks, with a beta of 2.47 indicating high volatility. Despite strong momentum metrics and a Zacks Rank #1 (Strong Buy) rating driven by upward earnings estimate revisions, OSCR trades at a reasonable valuation with a Price-to-Sales ratio of 0.68, suggesting significant upside potential. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Oscar Health Raises 2026 Operating Earnings Outlook as Margins Improve | Oscar Health raised its 2026 operating earnings guidance to $500M-$700M from $250M-$450M, driven by improved medical loss ratios (75% from 83%), disciplined pricing, and technology-driven expense efficiency. However, the company faces headwinds in the second half including 2%-4% monthly churn, rising medical costs, and open-enrollment spending. Revenue guidance remained unchanged at $18.7B-$19B. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Oscar Health Raises 2026 Operating Earnings Outlook as Margins Improve | Oscar Health raised its 2026 operating earnings guidance to $500M-$700M from $250M-$450M, driven by improved medical loss ratios (75% from 83%), disciplined pricing, and technology-driven expense efficiency. However, the company faces headwinds in the second half including 2%-4% monthly churn, rising medical costs, and open-enrollment spending. Revenue guidance remained unchanged at $18.7B-$19B. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Is Oscar Health Stock a Buy as Growth Surges but Valuation Stays Rich? | Oscar Health (OSCR) demonstrates impressive growth with Q2 revenues surging 70.4% to $4.9 billion and membership jumping 46.2% to 2.96 million, significantly outpacing a contracting ACA market. However, the stock trades at a premium valuation of 5.5X tangible book value versus the sub-industry's 1.2X, leaving limited room for disappointment. Execution risks include rising churn rates, increasing medical costs, and favorable reserve items that may not repeat, though the company maintains a strong capital base of $10.2 billion. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Is Oscar Health Stock a Buy as Growth Surges but Valuation Stays Rich? | Oscar Health (OSCR) demonstrates impressive growth with Q2 revenues surging 70.4% to $4.9 billion and membership jumping 46.2% to 2.96 million, significantly outpacing a contracting ACA market. However, the stock trades at a premium valuation of 5.5X tangible book value versus the sub-industry's 1.2X, leaving limited room for disappointment. Execution risks include rising churn rates, increasing medical costs, and favorable reserve items that may not repeat, though the company maintains a strong capital base of $10.2 billion. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Oscar Health Rallies 14.9% in 3 Months: Can the Gains Keep Going? | Oscar Health (OSCR) shares have gained 14.9% over three months, driven by 46.2% year-over-year membership growth to 2.96 million members and improved medical economics. The company's medical loss ratio improved to 75% from 83%, while SG&A expenses fell to 14.7% from 17.2%, supported by technology efficiencies. However, the stock faces headwinds from ACA market contraction and a valuation that already reflects higher expectations. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 1 |
| Oscar Health Rallies 14.9% in 3 Months: Can the Gains Keep Going? | Oscar Health (OSCR) shares have gained 14.9% over three months, driven by 46.2% year-over-year membership growth to 2.96 million members and improved medical economics. The company's medical loss ratio improved to 75% from 83%, while SG&A expenses fell to 14.7% from 17.2%, supported by technology efficiencies. However, the stock faces headwinds from ACA market contraction and a valuation that already reflects higher expectations. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 1 |
| Aon Expands Ukraine War Risk Insurance Facility With EBRD Support | Aon and the European Bank for Reconstruction and Development have expanded their Ukraine Recovery and Reconstruction Guarantee Facility, increasing guarantee capacity to €150 million from €110 million. The program has facilitated over €500 million in reinsurance coverage through nearly 10,000 policies and now includes additional local insurers and expanded coverage for gas assets and temporary warehouse inventory. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Aon Expands Ukraine War Risk Insurance Facility With EBRD Support | Aon and the European Bank for Reconstruction and Development have expanded their Ukraine Recovery and Reconstruction Guarantee Facility, increasing guarantee capacity to €150 million from €110 million. The program has facilitated over €500 million in reinsurance coverage through nearly 10,000 policies and now includes additional local insurers and expanded coverage for gas assets and temporary warehouse inventory. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Best Growth Stocks to Buy for October 13th | Zacks highlights three stocks with Rank #1 buy ratings and strong growth prospects: Petco Health and Wellness (WOOF) with 26.3% earnings estimate increase, Five Below (FIVE) with 15.2% earnings growth, and Oscar Health (OSCR) with 18.8% earnings growth. All three companies feature attractive PEG ratios and strong growth scores. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Best Growth Stocks to Buy for October 13th | Zacks highlights three stocks with Rank #1 buy ratings and strong growth prospects: Petco Health and Wellness (WOOF) with 26.3% earnings estimate increase, Five Below (FIVE) with 15.2% earnings growth, and Oscar Health (OSCR) with 18.8% earnings growth. All three companies feature attractive PEG ratios and strong growth scores. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Global Insurtech Market Size, Share, Trends, and Forecast to 2035 | AI, Cloud, and Automation Drive 41.45% CAGR, Creating a USD 638 Billion Opportunity | The global insurtech market is expected to expand from USD 14 billion in 2026 to USD 638 billion by 2035, driven by adoption of AI, cloud computing, blockchain, machine learning, and IoT. Health insurtech leads market share, while North America dominates regionally with Asia expected to achieve higher growth rates. Strategic partnerships between traditional insurers and startups are fueling innovation and scalability. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| Global Insurtech Market Size, Share, Trends, and Forecast to 2035 | AI, Cloud, and Automation Drive 41.45% CAGR, Creating a USD 638 Billion Opportunity | The global insurtech market is expected to expand from USD 14 billion in 2026 to USD 638 billion by 2035, driven by adoption of AI, cloud computing, blockchain, machine learning, and IoT. Health insurtech leads market share, while North America dominates regionally with Asia expected to achieve higher growth rates. Strategic partnerships between traditional insurers and startups are fueling innovation and scalability. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| Why Is OSCR Stock Rising Today? - Stocktwits | Why Is OSCR Stock Rising Today? Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| Best Growth Stocks to Buy for October 9th | Zacks highlights three stocks with Rank #1 (Strong Buy) ratings and strong growth prospects: Petco Health and Wellness (WOOF) with 26.3% earnings estimate increase, Five Below (FIVE) with 15.2% earnings increase, and Oscar Health (OSCR) with 18.8% earnings increase. All three companies feature attractive PEG ratios and strong growth scores. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Best Growth Stocks to Buy for October 9th | Zacks highlights three stocks with Rank #1 (Strong Buy) ratings and strong growth prospects: Petco Health and Wellness (WOOF) with 26.3% earnings estimate increase, Five Below (FIVE) with 15.2% earnings increase, and Oscar Health (OSCR) with 18.8% earnings increase. All three companies feature attractive PEG ratios and strong growth scores. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| OSCR 261009 40.00C (OSCR261009C40000) Stock Options Chain | Quotes & News - Moomoo | OSCR 261009 40.00C (OSCR261009C40000) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Oct 9, 2026 | neutral | 0 | 0.6 |
| Can Oscar Health Turn ACA Marketplace Growth Into Lasting Profits? | Oscar Health (OSCR) has surged 130% year-to-date driven by ACA marketplace expansion and plans to enter 150+ metro areas by 2027. However, the stock trades at a premium 4.94 price-to-book ratio versus the industry average of 2.64, and long-term profitability depends on disciplined underwriting and cost management rather than favorable policy conditions alone. Concentration risk from ACA exposure and potential subsidy policy changes pose headwinds. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Can Oscar Health Turn ACA Marketplace Growth Into Lasting Profits? | Oscar Health (OSCR) has surged 130% year-to-date driven by ACA marketplace expansion and plans to enter 150+ metro areas by 2027. However, the stock trades at a premium 4.94 price-to-book ratio versus the industry average of 2.64, and long-term profitability depends on disciplined underwriting and cost management rather than favorable policy conditions alone. Concentration risk from ACA exposure and potential subsidy policy changes pose headwinds. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Can Oscar Health Turn ACA Marketplace Growth Into Lasting Profits? - TradingView | Can Oscar Health Turn ACA Marketplace Growth Into Lasting Profits? TradingView | View source ↗ | TradingView | Oct 8, 2026 | neutral | 0 | 0.6 |
| Oscar Health, Inc. (OSCR) Advances While Market Declines: Some Information for Investors | Oscar Health (OSCR) gained 1.76% to $32.91, outperforming a declining market. The company holds a Zacks Rank #1 (Strong Buy) with consensus EPS estimates up 79.25% year-over-year and revenue projected at $4.72 billion (+58.14% YoY). Full-year earnings are expected at $1.83 per share (+208.28%) with revenue of $18.81 billion (+60.77%). Over the last 30 days, EPS estimates have risen 18.79%, though the stock trades at a Forward P/E of 17.64, above its industry average of 9.84. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Oscar Health, Inc. (OSCR) Advances While Market Declines: Some Information for Investors | Oscar Health (OSCR) gained 1.76% to $32.91, outperforming a declining market. The company holds a Zacks Rank #1 (Strong Buy) with consensus EPS estimates up 79.25% year-over-year and revenue projected at $4.72 billion (+58.14% YoY). Full-year earnings are expected at $1.83 per share (+208.28%) with revenue of $18.81 billion (+60.77%). Over the last 30 days, EPS estimates have risen 18.79%, though the stock trades at a Forward P/E of 17.64, above its industry average of 9.84. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Oscar Health, Inc. $OSCR Stock Sold by Glynn Capital Management LLC - MarketBeat | Oscar Health, Inc. $OSCR Stock Sold by Glynn Capital Management LLC MarketBeat | View source ↗ | MarketBeat | Oct 7, 2026 | neutral | 0 | 0.6 |
| Zacks Industry Outlook Prudential Financial, Assurant, Oscar and Horace Mann | The multiline insurance industry is positioned for growth driven by product diversification, improved pricing, and accelerated digitalization. Five stocks are highlighted as investment opportunities: Oscar Health and Horace Mann Educators (Zacks Rank #1), and Assurant, Principal Financial Group, and Prudential Financial (Zacks Rank #2). The industry ranks in the top 44% of Zacks industries with positive earnings outlooks, though it has underperformed the broader market in the past year. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.556 | 1 |
| Zacks Industry Outlook Prudential Financial, Assurant, Oscar and Horace Mann | The multiline insurance industry is positioned for growth driven by product diversification, improved pricing, and accelerated digitalization. Five stocks are highlighted as investment opportunities: Oscar Health and Horace Mann Educators (Zacks Rank #1), and Assurant, Principal Financial Group, and Prudential Financial (Zacks Rank #2). The industry ranks in the top 44% of Zacks industries with positive earnings outlooks, though it has underperformed the broader market in the past year. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.556 | 1 |
| Best Growth Stocks to Buy for October 7th | Zacks highlights three stocks with Rank #1 (Strong Buy) ratings and strong growth potential: Petco Health and Wellness (WOOF) with 26.3% earnings estimate increase, Five Below (FIVE) with 15.2% earnings increase, and Oscar Health (OSCR) with 55.1% earnings increase. All three companies feature favorable PEG ratios and strong growth scores. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Best Growth Stocks to Buy for October 7th | Zacks highlights three stocks with Rank #1 (Strong Buy) ratings and strong growth potential: Petco Health and Wellness (WOOF) with 26.3% earnings estimate increase, Five Below (FIVE) with 15.2% earnings increase, and Oscar Health (OSCR) with 55.1% earnings increase. All three companies feature favorable PEG ratios and strong growth scores. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| 5 Stocks to Buy From the Prosperous Multiline Insurance Industry | The Multiline Insurance industry is ranked in the top 44% of Zacks industries with positive earnings outlooks. While the sector faces softening pricing competition and inflation headwinds, product diversification, technology adoption, and M&A activity are expected to drive growth. Key players benefit from improved capital levels, higher interest rates boosting investment income, and digital transformation initiatives. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.556 | 1 |
| 5 Stocks to Buy From the Prosperous Multiline Insurance Industry | The Multiline Insurance industry is ranked in the top 44% of Zacks industries with positive earnings outlooks. While the sector faces softening pricing competition and inflation headwinds, product diversification, technology adoption, and M&A activity are expected to drive growth. Key players benefit from improved capital levels, higher interest rates boosting investment income, and digital transformation initiatives. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.556 | 1 |
| Oscar Health (NYSE:OSCR) Stock Forecast & Analyst Predictions - Simply Wall Street | Oscar Health (NYSE:OSCR) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| Oscar Health Trading at a Premium: Why Should You Still Buy It? | Oscar Health (OSCR) trades at a premium valuation of 4.65x book value but has gained 142.5% year-to-date, driven by strong membership growth to 2.96 million, 70% revenue surge to $4.88 billion in Q2, and improved profitability. The company targets 20% revenue CAGR through 2027 and 5% operating margin next year, supported by its technology-driven platform and expansion into 150+ new metropolitan areas. Analysts maintain optimistic sentiment with upward earnings estimate revisions. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 0.333 | 1 |
| Oscar Health Trading at a Premium: Why Should You Still Buy It? - TradingView | Oscar Health Trading at a Premium: Why Should You Still Buy It? TradingView | View source ↗ | TradingView | Oct 5, 2026 | neutral | 0 | 0.6 |
| Best Growth Stocks to Buy for October 5th | Zacks highlights three stocks with Rank #1 (Strong Buy) ratings and strong growth prospects: Petco Health and Wellness (WOOF) with 26.3% earnings estimate increase, Five Below (FIVE) with 15.2% earnings growth, and Oscar Health (OSCR) with 63.4% earnings estimate increase over the last 60 days. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 1 | 1 |
| Oscar Health, Inc. (OSCR) Stock Dips While Market Gains: Key Facts | Oscar Health (OSCR) closed at $29.90, down 3.05% in the most recent trading session, underperforming the S&P 500's 0.2% gain. Despite recent monthly gains of 1.68%, the stock faces headwinds from the Finance sector's 4.84% decline. However, analysts project strong earnings growth with EPS expected at -$0.11 (up 79.25% YoY) and revenue of $4.72 billion (up 58.14% YoY). The company holds a Zacks Rank #1 (Strong Buy) rating with a Forward P/E of 16.82, trading at a premium to its industry average of 9.52. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 1 | 1 |
| Oscar Health, Inc. (OSCR) Stock Dips While Market Gains: Key Facts | Oscar Health (OSCR) closed at $29.90, down 3.05% in the most recent trading session, underperforming the S&P 500's 0.2% gain. Despite recent monthly gains of 1.68%, the stock faces headwinds from the Finance sector's 4.84% decline. However, analysts project strong earnings growth with EPS expected at -$0.11 (up 79.25% YoY) and revenue of $4.72 billion (up 58.14% YoY). The company holds a Zacks Rank #1 (Strong Buy) rating with a Forward P/E of 16.82, trading at a premium to its industry average of 9.52. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 1 | 1 |
| Oscar Health, Inc. (NYSE:OSCR) Stock Now Rated "Hold" by Sell-Side Analysts - MarketBeat | Oscar Health, Inc. (NYSE:OSCR) Stock Now Rated "Hold" by Sell-Side Analysts MarketBeat | View source ↗ | MarketBeat | Sep 29, 2026 | neutral | 0 | 0.6 |
| Oscar Health (OSCR) Shares Moved, What Is Catching Investors' Attention? - Simply Wall Street | Oscar Health (OSCR) Shares Moved, What Is Catching Investors' Attention? Simply Wall Street | View source ↗ | Simply Wall Street | Sep 28, 2026 | neutral | 0 | 0.6 |
| Oscar Health (OSCR) Stock Looks Cheap Relative To Its Earnings Path - Yahoo Finance | Oscar Health (OSCR) Stock Looks Cheap Relative To Its Earnings Path Yahoo Finance | View source ↗ | Yahoo Finance | Sep 27, 2026 | neutral | 0 | 0.6 |
| After 14 years, Oscar Health's backer hands out 6.3 million shares. Its co-founder stays in control. - Stock Titan | After 14 years, Oscar Health's backer hands out 6.3 million shares. Its co-founder stays in control. Stock Titan | View source ↗ | Stock Titan | Sep 18, 2026 | neutral | 0 | 0.6 |
| Why Oscar Health (OSCR) Stock Is Up Today - Quiver Quantitative | Why Oscar Health (OSCR) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 14, 2026 | neutral | 0 | 0.6 |
| Oscar Health’s (NYSE:OSCR) Q2 CY2026 Sales Beat Estimates, Stock Jumps 11.8% - StockStory | Oscar Health’s (NYSE:OSCR) Q2 CY2026 Sales Beat Estimates, Stock Jumps 11.8% StockStory | View source ↗ | StockStory | Aug 6, 2026 | neutral | 0 | 0.6 |
| Oscar Health Stock Sinks Amid This Second-Half Risk - Investor's Business Daily | Oscar Health Stock Sinks Amid This Second-Half Risk Investor's Business Daily | View source ↗ | Investor's Business Daily | Aug 6, 2026 | neutral | 0 | 0.6 |
| Oscar Health (OSCR): A High Growth Momentum Stock Meeting Mark Minervini's Trend Template - ChartMill | Oscar Health (OSCR): A High Growth Momentum Stock Meeting Mark Minervini's Trend Template ChartMill | View source ↗ | ChartMill | Jul 14, 2026 | neutral | 0 | 0.6 |
| OSCR Stock Hits 5-Year High: Oscar Sees 'Healthy Tailwinds' In 2026 On Potential Upside To Guidance - Stocktwits | OSCR Stock Hits 5-Year High: Oscar Sees 'Healthy Tailwinds' In 2026 On Potential Upside To Guidance Stocktwits | View source ↗ | Stocktwits | Jun 8, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.